This information is intended for healthcare professionals based in Ireland.
If you are not a healthcare professional in Ireland, click here
This information is intended for healthcare professionals based in Ireland.
If you are not a healthcare professional in Ireland, click here
Choose ELIQUIS® to protect your patients with DVT / PE
ELIQUIS (apixaban) – an oral, direct factor Xa inhibitor - is indicated for:
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.1
- Prevention of Venous Thromboembolic Event (VTE) in adult patients who have undergone elective hip or knee replacement surgery.1
Robust clinical evidence for ELIQUIS in patients with DVT / PE
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Footnotes:
- CRNM = Clinically Relevant Non-Major DVT = Deep Vein Thrombosis PE = Pulmonary Embolism
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
- Agnelli G et al. N Engl J Med 2013; 369: 799–808.
- Agnelli G et al. N Engl J Med 2013; 368: 699–708.
- Weycker D et al. Thromb Haemost 2018; 118: 1951–1961.
Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie
Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com